Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery

This article was originally published in Start Up

Executive Summary

Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?

You may also be interested in...



Forma To Play To Its Strengths WIth Genentech Deal

Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.

Forma To Play To Its Strengths WIth Genentech Deal

Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.

Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns

As executives and investors scramble to find business models that more closely link investment and return, a handful of technology firms have alit on variations of a capital-efficient strategy: let someone else do the development dirty work.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel